Evidence map›Paper›PMID 35904235›Full record

ArticleEndocrine connections2022

Unmet needs in Cushing's syndrome: the patients' perspective.

Elena Valassi, Iacopo Chiodini, Richard A Feelders, Cornelie D Andela, Margueritta Abou-Hanna, Sarah Idres, Antoine Tabarin

Open access · goldAbstract read
In one paragraph

Article in Endocrine connections, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.0field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 16 citations in OpenAlex.

  1. Trial
  2. Observational
  3. Article
  4. Breaking Through Difficult-to-Control T2D: Targeting Hypercortisolism.Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2025
    Article
  5. Article
  6. Review
  7. Cushing syndrome.Nature reviews. Disease primers · 2025
    Review
  8. Hypercortisolism Is More Common Than You Think-Here's How to Find It.Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2024
    Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 3 countries.

Elena ValassiEndocrinology Department, Germans Trias i Pujol Hospital and Research Institute, Badalona, Barcelona, Spain.ORCID 0000-0002-3864-0105
Iacopo ChiodiniIRCCS, Istituto Auxologico Italiano, Milan, Italy.
Richard A FeeldersDivision of Endocrinology, Erasmus Medical Centre, Rotterdam, Netherlands.
Cornelie D AndelaDivision of Endocrinology and Centre for Endocrine Tumours, Leiden University Medical Centre, Leiden, Netherlands.
Margueritta Abou-HannaHRA Pharma Rare Diseases, Châtillon, France.
Sarah IdresHRA Pharma Rare Diseases, Châtillon, France.
Antoine TabarinDepartment of Endocrinology and INSERM U862 University and CHU of Bordeaux, Pessac, France.
HRA Pharma (France) · FRUniversity of Milan · ITErasmus University Rotterdam · NLInserm · FRLeiden University Medical Center · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Cushing's syndrome (CS) is a rare condition of chronically elevated cortisol levels resulting in diverse comorbidities, many of which endure beyond successful treatment affecting the quality of life. Few data are available concerning patients' experiences of diagnosis, care and persistent comorbidities. Objective: To assess CS patients' perspectives on the diagnostic and care journey to identify unmet therapeutic needs. Methods: A 12-item questionnaire was circulated in 2019 by the World Association for Pituitary Organisations. A parallel, 13-item questionnaire assessing physician perceptions on CS patient experiences was performed. Results: Three hundred twenty CS patients from 30 countries completed the questionnaire; 54% were aged 35-54 and 88% were female; 41% were in disease remission. The most burdensome symptom was obesity/weight gain (75%). For 49% of patients, time to diagnosis was over 2 years. Following treatment, 88.4% of patients reported ongoing symptoms including, fatigue (66.3%), muscle weakness (48.8%) and obesity/weight gain (41.9%). Comparisons with delay in diagnosis were significant for weight gain (P = 0.008) and decreased libido (P = 0.03). Forty physicians completed the parallel questionnaire which showed that generally, physicians poorly estimated the prevalence of comorbidities, particularly initial and persistent cognitive impairment. Only a minority of persistent comorbidities (occurrence in 1.3-66.3%; specialist treatment in 1.3-29.4%) were managed by specialists other than endocrinologists. 63% of patients were satisfied with treatment. Conclusion: This study confirms the delay in diagnosing CS. The high prevalence of persistent comorbidities following remission and differences in perceptions of health between patients and physicians highlight a probable deficiency in effective multidisciplinary management for CS comorbidities.

Indexed as

Cushing’s syndromemanagementpatient experiencepatient surveyquality of life

Identifiers

PMID35904235
PMCPMC9254293
OpenAlexW4282927298

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.